Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine
Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targe...
Saved in:
Published in | NPJ breast cancer Vol. 3; no. 1; pp. 3 - 10 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
15.02.2017
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53–7.22,
p
= 7.51 × 10
−19
). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28,
p
= 2.53× 10
−28
). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies.
Genetics: Expression signature identifies high-risk patients
A gene expression signature identifies breast cancer patients who do poorly after endocrine therapy and might benefit from extra treatment. A team led by John Bartlett and Paul Boutros from the Ontario Institute for Cancer Research in Toronto, Canada, measured the activity levels of 165 genes known to be involved in breast cancer development in tumor samples from 3825 patients with early estrogen receptor-positive disease. The patients received either endocrine therapies (tamoxifen or an aromatase inhibitor) alone or additional chemotherapy as well. The researchers identified a 95-gene expression signature that, when combined with a determination of whether the cancer has spread into the lymph nodes, can help predict which patients are at high risk of disease progression, regardless of whether they received chemotherapy or not. These patients could be prioritized for additional drug therapies. |
---|---|
AbstractList | Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53–7.22,
p
= 7.51 × 10
−19
). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28,
p
= 2.53× 10
−28
). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies. Genetics: Expression signature identifies high-risk patients A gene expression signature identifies breast cancer patients who do poorly after endocrine therapy and might benefit from extra treatment. A team led by John Bartlett and Paul Boutros from the Ontario Institute for Cancer Research in Toronto, Canada, measured the activity levels of 165 genes known to be involved in breast cancer development in tumor samples from 3825 patients with early estrogen receptor-positive disease. The patients received either endocrine therapies (tamoxifen or an aromatase inhibitor) alone or additional chemotherapy as well. The researchers identified a 95-gene expression signature that, when combined with a determination of whether the cancer has spread into the lymph nodes, can help predict which patients are at high risk of disease progression, regardless of whether they received chemotherapy or not. These patients could be prioritized for additional drug therapies. Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53–7.22, p = 7.51 × 10 −19 ). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10 −28 ). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies. Genetics: Expression signature identifies high-risk patients A gene expression signature identifies breast cancer patients who do poorly after endocrine therapy and might benefit from extra treatment. A team led by John Bartlett and Paul Boutros from the Ontario Institute for Cancer Research in Toronto, Canada, measured the activity levels of 165 genes known to be involved in breast cancer development in tumor samples from 3825 patients with early estrogen receptor-positive disease. The patients received either endocrine therapies (tamoxifen or an aromatase inhibitor) alone or additional chemotherapy as well. The researchers identified a 95-gene expression signature that, when combined with a determination of whether the cancer has spread into the lymph nodes, can help predict which patients are at high risk of disease progression, regardless of whether they received chemotherapy or not. These patients could be prioritized for additional drug therapies. Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53–7.22, p = 7.51 × 10 −19 ). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10 −28 ). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies. A gene expression signature identifies breast cancer patients who do poorly after endocrine therapy and might benefit from extra treatment. A team led by John Bartlett and Paul Boutros from the Ontario Institute for Cancer Research in Toronto, Canada, measured the activity levels of 165 genes known to be involved in breast cancer development in tumor samples from 3825 patients with early estrogen receptor-positive disease. The patients received either endocrine therapies (tamoxifen or an aromatase inhibitor) alone or additional chemotherapy as well. The researchers identified a 95-gene expression signature that, when combined with a determination of whether the cancer has spread into the lymph nodes, can help predict which patients are at high risk of disease progression, regardless of whether they received chemotherapy or not. These patients could be prioritized for additional drug therapies. Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53-7.22, p = 7.51 × 10-19). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10-28). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies. Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53-7.22, = 7.51 × 10 ). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, = 2.53× 10 ). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies. Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic chemotherapy treatment is necessary for others. The clinical challenges in managing high-risk women are to identify existing and novel druggable targets, and to identify those who would benefit from these therapies. Therefore, we performed mRNA abundance analysis using the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial pathology cohort to identify a signature of residual risk following endocrine therapy and pathways that are potentially druggable. A panel of genes compiled from academic and commercial multiparametric tests as well as genes of importance to breast cancer pathogenesis was used to profile 3825 patients. A signature of 95 genes, including nodal status, was validated to stratify endocrine-treated patients into high-risk and low-risk groups based on distant relapse-free survival (DRFS; Hazard Ratio = 5.05, 95% CI 3.53–7.22, p = 7.51 × 10−19). This risk signature was also found to perform better than current multiparametric tests. When the 95-gene prognostic signature was applied to all patients in the validation cohort, including patients who received adjuvant chemotherapy, the signature remained prognostic (HR = 4.76, 95% CI 3.61-6.28, p = 2.53× 10−28). Functional gene interaction analyses identified six significant modules representing pathways involved in cell cycle control, mitosis and receptor tyrosine signaling; containing a number of genes with existing targeted therapies for use in breast or other malignancies. Thus the identification of high-risk patients using this prognostic signature has the potential to also prioritize patients for treatment with these targeted therapies. |
ArticleNumber | 3 |
Author | Brookes, Cassandra L. D’Costa, Alister Dirix, Luc Yao, Cindy Q. Boutros, Paul C. Bayani, Jane Markopoulos, Christos Quintayo, Mary Anne Kieback, Dirk G. Seynaeve, Caroline Haider, Syed Hasenburg, Annette van de Velde, Cornelis J. H. Bartlett, John M. S. Rea, Daniel Yan, Fu |
Author_xml | – sequence: 1 givenname: Jane surname: Bayani fullname: Bayani, Jane organization: Ontario Institute for Cancer Research – sequence: 2 givenname: Cindy Q. surname: Yao fullname: Yao, Cindy Q. organization: Ontario Institute for Cancer Research – sequence: 3 givenname: Mary Anne surname: Quintayo fullname: Quintayo, Mary Anne organization: Ontario Institute for Cancer Research – sequence: 4 givenname: Fu surname: Yan fullname: Yan, Fu organization: Ontario Institute for Cancer Research – sequence: 5 givenname: Syed surname: Haider fullname: Haider, Syed organization: Ontario Institute for Cancer Research – sequence: 6 givenname: Alister surname: D’Costa fullname: D’Costa, Alister organization: Ontario Institute for Cancer Research – sequence: 7 givenname: Cassandra L. surname: Brookes fullname: Brookes, Cassandra L. organization: Cancer Research UK Clinical Trials Unit, University of Birmingham – sequence: 8 givenname: Cornelis J. H. surname: van de Velde fullname: van de Velde, Cornelis J. H. organization: Leiden University Medical Center – sequence: 9 givenname: Annette surname: Hasenburg fullname: Hasenburg, Annette organization: University of Mainz – sequence: 10 givenname: Dirk G. surname: Kieback fullname: Kieback, Dirk G. organization: Helios Medical Center – sequence: 11 givenname: Christos surname: Markopoulos fullname: Markopoulos, Christos organization: Athens University Medical School – sequence: 12 givenname: Luc surname: Dirix fullname: Dirix, Luc organization: St. Augustinus Hospital – sequence: 13 givenname: Caroline surname: Seynaeve fullname: Seynaeve, Caroline organization: Erasmus MC Cancer Institute – sequence: 14 givenname: Daniel surname: Rea fullname: Rea, Daniel organization: Cancer Research UK Clinical Trials Unit, University of Birmingham – sequence: 15 givenname: Paul C. surname: Boutros fullname: Boutros, Paul C. email: Paul.Boutros@oicr.on.ca organization: Ontario Institute for Cancer Research, University of Toronto – sequence: 16 givenname: John M. S. surname: Bartlett fullname: Bartlett, John M. S. email: John.Bartlett@oicr.on.ca organization: Ontario Institute for Cancer Research, Cancer Research UK Clinical Trials Unit, University of Birmingham, University of Toronto |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28649643$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ks1rFDEYh4NUbK39A7xIwIuXqfnOzEWQorZQ8aLnkEnerFlmk5rMFPrfm3XqshW85PPJk7zh9xKdpJwAodeUXFLC-_dVUMl4R6jqCCG8k8_QGeNadEJpfXI0PkUXtW4bQ4XqB0lfoFPWKzEowc-Q_5oncMtkC65zsXMM0bU2J5wDBlumBzwWsHXGziYHBUcPaU9Bxb4sGzzbsoG54jm3ebyHgwY83oGPLiZ4hZ4HO1W4eOzP0Y_Pn75fXXe3377cXH287Zzkau6oGsBbOzItuGbKDcBCH6SWilurIIAImrphFGwERuSgYPTEK6I8t8H3Iz9HN6vXZ7s1dyXubHkw2UbzZyGXjbFljm4CAz1w4NoN1nHBYOwld5K2G1TQEJxrrg-r624ZWx2uVV3s9ET6dCfFn2aT740UQiqqmuDdo6DkXwvU2exidTBNNkFeqqED5T0nXMmGvv0H3ealpPZVjRKaCKXY0Ci6Uq7kWguEw2MoMftImDUSpkXC7CNh9uY3x1UcTvwNQAPYCtS2lTZQjq7-r_U3PQzF3Q |
CitedBy_id | crossref_primary_10_1371_journal_pone_0238593 crossref_primary_10_1158_1078_0432_CCR_19_1038 crossref_primary_10_3389_fonc_2022_907684 crossref_primary_10_1016_j_celrep_2024_113826 crossref_primary_10_1038_s41523_021_00297_7 crossref_primary_10_1200_PO_18_00373 crossref_primary_10_1038_s41523_021_00301_0 crossref_primary_10_3390_cancers16081480 crossref_primary_10_1016_j_jmoldx_2022_04_002 crossref_primary_10_3389_fonc_2023_1280943 crossref_primary_10_1097_CCO_0000000000000490 crossref_primary_10_1038_s41585_021_00500_1 crossref_primary_10_1200_EDBK_200981 crossref_primary_10_1186_s13039_024_00680_6 |
Cites_doi | 10.1158/1078-0432.CCR-07-5026 10.1200/JCO.2010.30.3677 10.1158/1078-0432.CCR-10-1282 10.1007/s12325-013-0060-1 10.1200/JCO.2009.23.1274 10.1371/journal.pone.0068252 10.1093/bioinformatics/bts188 10.1091/mbc.02-02-0030 10.1200/JCO.2007.14.3222 10.1200/JCO.2011.35.2245 10.1093/annonc/mds080 10.1016/S0140-6736(05)66544-0 10.1056/NEJMoa041588 10.1158/1078-0432.CCR-12-0286 10.1038/35021093 10.1007/s10549-014-3238-6 10.1016/j.ejca.2010.03.039 10.1093/annonc/mdu456 10.1186/bcr2419 10.1200/JCO.2013.50.9984 10.1200/JCO.2005.04.7985 10.1007/s10549-013-2628-5 10.1200/JCO.2010.31.2835 10.1016/j.clon.2012.10.005 10.1200/JCO.2015.62.3504 10.1056/NEJMoa021967 10.1634/theoncologist.2009-0010 10.1186/1471-2164-10-424 10.1038/bjc.2012.166 10.1016/S0140-6736(10)62312-4 10.1016/S1470-2045(14)71159-3 10.1038/bjc.2013.609 10.1200/JCO.2006.09.2775 10.1093/jnci/djw050 |
ContentType | Journal Article |
Copyright | The Author(s) 2017 Copyright Nature Publishing Group Feb 2017 |
Copyright_xml | – notice: The Author(s) 2017 – notice: Copyright Nature Publishing Group Feb 2017 |
DBID | C6C NPM AAYXX CITATION 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1038/s41523-016-0003-5 |
DatabaseName | SpringerOpen PubMed CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic PubMed Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature Open Access Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2374-4677 |
EndPage | 10 |
ExternalDocumentID | oai_doaj_org_article_e8e3e37c9ac342eb853c51e4f6f7efcc 10_1038_s41523_016_0003_5 28649643 |
Genre | Journal Article |
GrantInformation_xml | – fundername: Cancer Research UK grantid: 15958 |
GroupedDBID | 0R~ 3V. 53G 5VS 7X7 8FI 8FJ AAJSJ ABUWG ACGFS ACSMW ADBBV AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BCNDV BENPR BPHCQ BVXVI C6C CCPQU EBLON EBS EJD EMOBN FYUFA GROUPED_DOAJ HMCUK HYE M~E NAO NO~ OK1 PGMZT PIMPY PQQKQ PROAC RNT RPM SNYQT UKHRP NPM AAYXX CITATION 7XB 8FK AZQEC DWQXO K9. PQEST PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c536t-169edaab2743726c9e2f8f57563aa6efe4f71c9b42be20596ebd0d606d3afd8b3 |
IEDL.DBID | RPM |
ISSN | 2374-4677 |
IngestDate | Tue Oct 22 14:42:53 EDT 2024 Tue Sep 17 21:28:43 EDT 2024 Fri Oct 25 22:52:13 EDT 2024 Thu Oct 10 18:59:27 EDT 2024 Thu Nov 21 23:27:00 EST 2024 Sat Nov 02 12:23:47 EDT 2024 Fri Oct 11 20:46:12 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c536t-169edaab2743726c9e2f8f57563aa6efe4f71c9b42be20596ebd0d606d3afd8b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445616/ |
PMID | 28649643 |
PQID | 1947046629 |
PQPubID | 2041925 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e8e3e37c9ac342eb853c51e4f6f7efcc pubmedcentral_primary_oai_pubmedcentral_nih_gov_5445616 proquest_miscellaneous_1913830365 proquest_journals_1947046629 crossref_primary_10_1038_s41523_016_0003_5 pubmed_primary_28649643 springer_journals_10_1038_s41523_016_0003_5 |
PublicationCentury | 2000 |
PublicationDate | 2017-02-15 |
PublicationDateYYYYMMDD | 2017-02-15 |
PublicationDate_xml | – month: 02 year: 2017 text: 2017-02-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: United States |
PublicationTitle | NPJ breast cancer |
PublicationTitleAbbrev | npj Breast Cancer |
PublicationTitleAlternate | NPJ Breast Cancer |
PublicationYear | 2017 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | Afentakis (CR15) 2013; 140 Clemens (CR20) 2015; 149 van de Velde (CR19) 2011; 377 Finn (CR24) 2009; 11 Wolff (CR32) 2013; 31 CR17 van de Vijver (CR11) 2002; 347 Finn (CR23) 2015; 16 Paik (CR6) 2006; 24 Barton (CR35) 2012; 106 Ma (CR12) 2008; 14 Cardoso (CR10) 2008; 26 Muller (CR14) 2013; 8 Schoffski (CR21) 2009; 14 Schoffski (CR22) 2010; 46 Hosford, Miller (CR27) 2014; 7 Bartlett (CR28) 2011; 29 Dowsett (CR2) 2010; 28 Prat (CR18) 2012; 23 Chia (CR7) 2012; 18 Bartlett (CR4) 2013; 25 Cuzick (CR36) 2011; 29 Abe (CR1) 2005; 365 Colleoni (CR3) 2016; 34 Wolff (CR31) 2007; 25 Paik (CR5) 2004; 351 Perou (CR9) 2000; 406 Piccart (CR25) 2014; 25 Hammond, Hayes, Wolff (CR30) 2011; 29 Waggott (CR33) 2012; 28 Whitfield (CR13) 2002; 13 Yardley (CR26) 2013; 30 Toussaint (CR34) 2009; 10 Nielsen (CR8) 2010; 16 Cuzick (CR16) 2011; 29 Bartlett (CR29) 2013; 109 3_CR17 S Barton (3_CR35) 2012; 106 O Abe (3_CR1) 2005; 365 AC Wolff (3_CR31) 2007; 25 F Cardoso (3_CR10) 2008; 26 S Paik (3_CR5) 2004; 351 M Afentakis (3_CR15) 2013; 140 SR Hosford (3_CR27) 2014; 7 SK Chia (3_CR7) 2012; 18 P Schoffski (3_CR22) 2010; 46 J Bartlett (3_CR4) 2013; 25 D Waggott (3_CR33) 2012; 28 ME Hammond (3_CR30) 2011; 29 RS Finn (3_CR23) 2015; 16 M Dowsett (3_CR2) 2010; 28 BM Muller (3_CR14) 2013; 8 MR Clemens (3_CR20) 2015; 149 XJ Ma (3_CR12) 2008; 14 DA Yardley (3_CR26) 2013; 30 J Cuzick (3_CR36) 2011; 29 TO Nielsen (3_CR8) 2010; 16 S Paik (3_CR6) 2006; 24 CJ van de Velde (3_CR19) 2011; 377 AC Wolff (3_CR32) 2013; 31 J Toussaint (3_CR34) 2009; 10 CM Perou (3_CR9) 2000; 406 JM Bartlett (3_CR28) 2011; 29 JM Bartlett (3_CR29) 2013; 109 MJ van de Vijver (3_CR11) 2002; 347 RS Finn (3_CR24) 2009; 11 P Schoffski (3_CR21) 2009; 14 J Cuzick (3_CR16) 2011; 29 M Colleoni (3_CR3) 2016; 34 M Piccart (3_CR25) 2014; 25 ML Whitfield (3_CR13) 2002; 13 A Prat (3_CR18) 2012; 23 |
References_xml | – volume: 14 start-page: 2601 year: 2008 end-page: 2608 ident: CR12 article-title: A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-5026 contributor: fullname: Ma – volume: 29 start-page: 1531 year: 2011 end-page: 1538 ident: CR28 article-title: Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.30.3677 contributor: fullname: Bartlett – volume: 16 start-page: 5222 year: 2010 end-page: 5232 ident: CR8 article-title: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer publication-title: Clin. Cancer. Res. doi: 10.1158/1078-0432.CCR-10-1282 contributor: fullname: Nielsen – volume: 30 start-page: 870 year: 2013 end-page: 884 ident: CR26 article-title: Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis publication-title: Adv. Ther. doi: 10.1007/s12325-013-0060-1 contributor: fullname: Yardley – volume: 28 start-page: 509 year: 2010 end-page: 518 ident: CR2 article-title: Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.23.1274 contributor: fullname: Dowsett – volume: 8 start-page: e68252 year: 2013 ident: CR14 article-title: The EndoPredict gene-expression assay in clinical practice - performance and impact on clinical decisions publication-title: PLoS. One doi: 10.1371/journal.pone.0068252 contributor: fullname: Muller – volume: 28 start-page: 1546 year: 2012 end-page: 1548 ident: CR33 article-title: NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts188 contributor: fullname: Waggott – volume: 13 start-page: 1977 year: 2002 end-page: 2000 ident: CR13 article-title: Identification of genes periodically expressed in the human cell cycle and their expression in tumors publication-title: Mol. Biol. Cell doi: 10.1091/mbc.02-02-0030 contributor: fullname: Whitfield – volume: 26 start-page: 729 year: 2008 end-page: 735 ident: CR10 article-title: Clinical application of the 70-gene profile: the MINDACT trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.14.3222 contributor: fullname: Cardoso – volume: 29 start-page: e458 year: 2011 ident: CR30 article-title: Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.2245 contributor: fullname: Wolff – volume: 23 start-page: 2866 year: 2012 end-page: 2873 ident: CR18 article-title: Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen publication-title: Ann. Oncol. doi: 10.1093/annonc/mds080 contributor: fullname: Prat – volume: 365 start-page: 1687 year: 2005 end-page: 1717 ident: CR1 article-title: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(05)66544-0 contributor: fullname: Abe – volume: 351 start-page: 2817 year: 2004 end-page: 2826 ident: CR5 article-title: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa041588 contributor: fullname: Paik – volume: 18 start-page: 4465 year: 2012 end-page: 4472 ident: CR7 article-title: A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen publication-title: Clin. Cancer. Res. doi: 10.1158/1078-0432.CCR-12-0286 contributor: fullname: Chia – volume: 406 start-page: 747 year: 2000 end-page: 752 ident: CR9 article-title: Molecular portraits of human breast tumours publication-title: Nature doi: 10.1038/35021093 contributor: fullname: Perou – volume: 149 start-page: 171 year: 2015 end-page: 179 ident: CR20 article-title: Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer publication-title: Breast. Cancer Res. Treat. doi: 10.1007/s10549-014-3238-6 contributor: fullname: Clemens – volume: 46 start-page: 2206 year: 2010 end-page: 2215 ident: CR22 article-title: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2010.03.039 contributor: fullname: Schoffski – volume: 25 start-page: 2357 year: 2014 end-page: 2362 ident: CR25 article-title: Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger publication-title: Ann. Oncol. doi: 10.1093/annonc/mdu456 contributor: fullname: Piccart – volume: 11 start-page: R77 year: 2009 ident: CR24 article-title: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro publication-title: Breast Cancer Res. doi: 10.1186/bcr2419 contributor: fullname: Finn – volume: 31 start-page: 3997 year: 2013 end-page: 4013 ident: CR32 article-title: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2013.50.9984 contributor: fullname: Wolff – volume: 24 start-page: 3726 year: 2006 end-page: 3734 ident: CR6 article-title: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.04.7985 contributor: fullname: Paik – volume: 140 start-page: 253 year: 2013 end-page: 262 ident: CR15 article-title: Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-013-2628-5 contributor: fullname: Afentakis – volume: 29 start-page: 4273 year: 2011 end-page: 4278 ident: CR36 article-title: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.31.2835 contributor: fullname: Cuzick – volume: 25 start-page: 109 year: 2013 end-page: 116 ident: CR4 article-title: Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial publication-title: Clin. Oncol. (R. Coll. Radiol.). doi: 10.1016/j.clon.2012.10.005 contributor: fullname: Bartlett – ident: CR17 – volume: 29 start-page: 4273 year: 2011 end-page: 4278 ident: CR16 article-title: Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 Immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.31.2835 contributor: fullname: Cuzick – volume: 34 start-page: 927 year: 2016 end-page: 935 ident: CR3 article-title: Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.3504 contributor: fullname: Colleoni – volume: 347 start-page: 1999 year: 2002 end-page: 2009 ident: CR11 article-title: A gene-expression signature as a predictor of survival in breast cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa021967 contributor: fullname: van de Vijver – volume: 14 start-page: 559 year: 2009 end-page: 570 ident: CR21 article-title: Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology publication-title: Oncologist doi: 10.1634/theoncologist.2009-0010 contributor: fullname: Schoffski – volume: 10 start-page: 424 year: 2009 ident: CR34 article-title: Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues publication-title: BMC. Genomics doi: 10.1186/1471-2164-10-424 contributor: fullname: Toussaint – volume: 7 start-page: 203 year: 2014 end-page: 215 ident: CR27 article-title: Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways publication-title: Pharmgenomics Pers. Med. contributor: fullname: Miller – volume: 106 start-page: 1760 year: 2012 end-page: 1765 ident: CR35 article-title: Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer publication-title: Br. J. Cancer doi: 10.1038/bjc.2012.166 contributor: fullname: Barton – volume: 377 start-page: 321 year: 2011 end-page: 331 ident: CR19 article-title: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(10)62312-4 contributor: fullname: van de Velde – volume: 16 start-page: 25 year: 2015 end-page: 35 ident: CR23 article-title: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)71159-3 contributor: fullname: Finn – volume: 109 start-page: 2453 year: 2013 end-page: 2461 ident: CR29 article-title: Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.609 contributor: fullname: Bartlett – volume: 25 start-page: 118 year: 2007 end-page: 145 ident: CR31 article-title: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2006.09.2775 contributor: fullname: Wolff – volume: 13 start-page: 1977 year: 2002 ident: 3_CR13 publication-title: Mol. Biol. Cell doi: 10.1091/mbc.02-02-0030 contributor: fullname: ML Whitfield – volume: 29 start-page: e458 year: 2011 ident: 3_CR30 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.2245 contributor: fullname: ME Hammond – volume: 34 start-page: 927 year: 2016 ident: 3_CR3 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.62.3504 contributor: fullname: M Colleoni – volume: 351 start-page: 2817 year: 2004 ident: 3_CR5 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa041588 contributor: fullname: S Paik – volume: 109 start-page: 2453 year: 2013 ident: 3_CR29 publication-title: Br. J. Cancer doi: 10.1038/bjc.2013.609 contributor: fullname: JM Bartlett – volume: 18 start-page: 4465 year: 2012 ident: 3_CR7 publication-title: Clin. Cancer. Res. doi: 10.1158/1078-0432.CCR-12-0286 contributor: fullname: SK Chia – volume: 365 start-page: 1687 year: 2005 ident: 3_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(05)66544-0 contributor: fullname: O Abe – volume: 23 start-page: 2866 year: 2012 ident: 3_CR18 publication-title: Ann. Oncol. doi: 10.1093/annonc/mds080 contributor: fullname: A Prat – volume: 11 start-page: R77 year: 2009 ident: 3_CR24 publication-title: Breast Cancer Res. doi: 10.1186/bcr2419 contributor: fullname: RS Finn – volume: 140 start-page: 253 year: 2013 ident: 3_CR15 publication-title: Breast Cancer Res. Treat. doi: 10.1007/s10549-013-2628-5 contributor: fullname: M Afentakis – volume: 28 start-page: 509 year: 2010 ident: 3_CR2 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.23.1274 contributor: fullname: M Dowsett – volume: 16 start-page: 5222 year: 2010 ident: 3_CR8 publication-title: Clin. Cancer. Res. doi: 10.1158/1078-0432.CCR-10-1282 contributor: fullname: TO Nielsen – volume: 14 start-page: 559 year: 2009 ident: 3_CR21 publication-title: Oncologist doi: 10.1634/theoncologist.2009-0010 contributor: fullname: P Schoffski – volume: 31 start-page: 3997 year: 2013 ident: 3_CR32 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2013.50.9984 contributor: fullname: AC Wolff – volume: 25 start-page: 118 year: 2007 ident: 3_CR31 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2006.09.2775 contributor: fullname: AC Wolff – ident: 3_CR17 doi: 10.1093/jnci/djw050 – volume: 29 start-page: 4273 year: 2011 ident: 3_CR36 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.31.2835 contributor: fullname: J Cuzick – volume: 26 start-page: 729 year: 2008 ident: 3_CR10 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2007.14.3222 contributor: fullname: F Cardoso – volume: 46 start-page: 2206 year: 2010 ident: 3_CR22 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2010.03.039 contributor: fullname: P Schoffski – volume: 28 start-page: 1546 year: 2012 ident: 3_CR33 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts188 contributor: fullname: D Waggott – volume: 8 start-page: e68252 year: 2013 ident: 3_CR14 publication-title: PLoS. One doi: 10.1371/journal.pone.0068252 contributor: fullname: BM Muller – volume: 25 start-page: 109 year: 2013 ident: 3_CR4 publication-title: Clin. Oncol. (R. Coll. Radiol.). doi: 10.1016/j.clon.2012.10.005 contributor: fullname: J Bartlett – volume: 149 start-page: 171 year: 2015 ident: 3_CR20 publication-title: Breast. Cancer Res. Treat. doi: 10.1007/s10549-014-3238-6 contributor: fullname: MR Clemens – volume: 25 start-page: 2357 year: 2014 ident: 3_CR25 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdu456 contributor: fullname: M Piccart – volume: 347 start-page: 1999 year: 2002 ident: 3_CR11 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa021967 contributor: fullname: MJ van de Vijver – volume: 7 start-page: 203 year: 2014 ident: 3_CR27 publication-title: Pharmgenomics Pers. Med. contributor: fullname: SR Hosford – volume: 106 start-page: 1760 year: 2012 ident: 3_CR35 publication-title: Br. J. Cancer doi: 10.1038/bjc.2012.166 contributor: fullname: S Barton – volume: 29 start-page: 4273 year: 2011 ident: 3_CR16 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.31.2835 contributor: fullname: J Cuzick – volume: 16 start-page: 25 year: 2015 ident: 3_CR23 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(14)71159-3 contributor: fullname: RS Finn – volume: 10 start-page: 424 year: 2009 ident: 3_CR34 publication-title: BMC. Genomics doi: 10.1186/1471-2164-10-424 contributor: fullname: J Toussaint – volume: 24 start-page: 3726 year: 2006 ident: 3_CR6 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.04.7985 contributor: fullname: S Paik – volume: 29 start-page: 1531 year: 2011 ident: 3_CR28 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.30.3677 contributor: fullname: JM Bartlett – volume: 406 start-page: 747 year: 2000 ident: 3_CR9 publication-title: Nature doi: 10.1038/35021093 contributor: fullname: CM Perou – volume: 14 start-page: 2601 year: 2008 ident: 3_CR12 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-5026 contributor: fullname: XJ Ma – volume: 377 start-page: 321 year: 2011 ident: 3_CR19 publication-title: Lancet doi: 10.1016/S0140-6736(10)62312-4 contributor: fullname: CJ van de Velde – volume: 30 start-page: 870 year: 2013 ident: 3_CR26 publication-title: Adv. Ther. doi: 10.1007/s12325-013-0060-1 contributor: fullname: DA Yardley |
SSID | ssj0001468951 |
Score | 2.1511817 |
Snippet | Many women with hormone receptor-positive early breast cancer can be managed effectively with endocrine therapies alone. However, additional systemic... Genetics: Expression signature identifies high-risk patients A gene expression signature identifies breast cancer patients who do poorly after endocrine... |
SourceID | doaj pubmedcentral proquest crossref pubmed springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 3 |
SubjectTerms | 631/67/1347 692/53/2422 Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Cancer therapies Cell Biology Cell cycle Chemotherapy Endocrine therapy Gene expression Human Genetics Oncology |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JL6btuk6JCTy0ma0key8cmJITC5pRAbkKPUZuLt-x6_39Gkr3s9kEvPdoyZpgZeb7RjL9h7BOBYNAN2BqVD7WCBuq-dbG2lErEHjoFmUxneQ1Xt-rbXXu3N-or9YQVeuCiuFPUKFF2vrdeKoGOwotvG1QRYofR-_z1XYi9ZCqfrijQhB3mMqbUp5sUqVLrEKQfqWXdHgSizNf_J5D5e6_kLwXTHIcun7GnE4DkX4vgz9kjHF6wx8upRP6SheU88JYXStw4ncrxVeSY6Iy5S43oI_fJ4Gt-H0rDEG54WG-_89IbvuHjiq7pW7h7DQY-V-JfsdvLi5vzq3oapVD7VsJYN9BjsNZRDio7Ab5HEXUkqAbSWsBI-uwa3zslHIo0kQddWARKboK0MWgnX7OjYTXgW8Y7J3oIzltNyEBp4ZyQkWBZu7BugRIq9nnWq_lZGDNMrnRLbYoRTOoqS0YwbcXOkuZ3Dyay63yDXMBMLmD-5QIVO57tZqYduDFNrzrK_UH0Ffu4W6a9kwoidsDVNj3TUIJOMZzkeFPMvJNEaFCJq6xi3YEDHIh6uDLc_8j83InfiJy-Yl9mV9kT62-aePc_NPGePREJdqSBNe0xOxrXWzwh0DS6D3l_PACzeRZb priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9QwDI5gkRAXxJvCgoLECVTtNEmT9IQAsVohDSdWmluUh7Pspd2ddv4_dh-zDK9j26hyYyf-HLufGXuLIFjbSvsSVEyl0pUumzrk0mMokRttlB7JdNbf9Nm5-rqpN_OBWz-XVS574rhRpy7SGfkJBtsGYzktmg9X1yV1jaLs6txC4za7Uwl05WjPZmNuzliUtogglmSmtCc9-SsqINL0O7Us6wN3NLL2_w1q_lkx-VvadPRGpw_Y_RlG8o-T3h-yW9A-YnfXc6L8MUvrpe0tn4hx83w2x7vMgUiNeaBy9IFHUvuWX6apbAh6nra7Cz5ViPd86PAad8T9ayDxJR__hJ2ffvn--aycGyqUsZZ6KCvdQPI-YCQqjdCxAZFtRsCmpfcaMqhsqtgEJQII6ssDIa0ShjhJ-pxskE_ZUdu18JxxE0SjU4jeIj5QVoQgZEZwVq98WIHUBXu3zKu7mngz3JjvltZNSnBUW0ZKcHXBPtHM7wcS5fV4o9teuHkFObAgQZrY-CiVgIA4I9YViqyzgRxjwY4Xvbl5HfbuxmoK9mb_GFcQpUV8C92OxlQYpqMnRzmeTWreSyKsVsRYVjBzYAAHoh4-aS9_jCzdxHKEpl-w94up_CLWv2bixf8_4iW7JwhWUEOa-pgdDdsdvEJQNITXo-X_BJ_LDDM priority: 102 providerName: ProQuest – databaseName: SpringerOpen dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9QwDI5gkRAXxJvCgoLECVQxTVInPcKI1QppOLHS3qo8HNhLZzXT-f_YfQwUlgPHtmllxXb9OXa-CPGWQDC4CnyJJqbSQAVlU4dcekolcgPWwECms_kK5xfmy2V9OZFF816YRf1euw97DjDc8QO8_1mX9W1xh0KwZWNew_rXcooBR2Bhrlve9OYi8gwE_Tehyr-bI_-okA6B5-yBuD8hRvlxVPFDcQu7R-LuZqqJPxZpM59wK0cO3Dwtw8ltlsj8xTJw53kvI2t4J6_S2CGEe5l2h-9ybAbfy35L1_TzO34Gk5xL70_Exdnnb-vzcjo7oYy1hr6soMHkfaCkU1sFsUGVXSZsBtp7wIwm2yo2waiAio_gwZBWibKZpH1OLuin4qTbdvhcSBtUAylE7wgKGKdCUDoTDqtXPqxQQyHezfPaXo8UGe1Q2tauHZXQchsZK6GtC_GJZ_44kNmthxuk9HZylhYdatQ2Nj5qozAQpIh1RSJDtphjLMTprLd2crl9WzXGUrIPqinEm-NjchaugPgOtwceU1FGTkGb5Hg2qvkoiXJgmJysEHZhAAtRl0-6qx8DITcTGpGVF-L9bCq_ifWvmXjxX6NfinuKAQUfRVOfipN-d8BXBIf68HpwhJ8WfgSF priority: 102 providerName: Springer Nature |
Title | Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine |
URI | https://link.springer.com/article/10.1038/s41523-016-0003-5 https://www.ncbi.nlm.nih.gov/pubmed/28649643 https://www.proquest.com/docview/1947046629 https://search.proquest.com/docview/1913830365 https://pubmed.ncbi.nlm.nih.gov/PMC5445616 https://doaj.org/article/e8e3e37c9ac342eb853c51e4f6f7efcc |
Volume | 3 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEB6SFEovpe-6TRcVempxdi3JY_vYLAmhsCGUBvZm9EwXEjvsev9_R7K9ZPu49GjLyINm5PlG83kG4BOBYCwzVKmTxqYSM0yrXPtUUSjhKywkxmI6i0u8uJbflvnyAPLxX5hI2jd6ddLc3p00q5-RW3l_Z6YjT2x6tZiHAjI06_QQDsn9PgjR48GKxJJgw5jBFOV0E5xUYA1h-IdapKFbDS9RhlJUe-4oVu3_G9T8kzH5W9o0eqPzZ_B0gJHsay_uczhwzQt4vBgS5S_BLsa2t6wvjOuHsznWeuZCUWOmAx29Yyaofc1WtqcNuQ2z6-0N6xniG9a1dE1fxN00zrIxH_8Krs_Pfswv0qGhQmpygV2aYeWsUpoiUVFwNJXjvvQE2FAohc476YvMVFpy7Xjoy-O0nVkKcaxQ3pZavIajpm3cW2CF5hVabVRJ-ECWXGsuPIGzfKb0zAlM4PO4rvV9XzejjvluUda9PurALQv6qPMETsPK7x4MJa_jjXZ9Uw-Kr13phBOFqZQRkjtNOMPkGYmMvnDemASOR73Vwz7c1Fkli5lE5FUCH3fDtINCWkQ1rt2GZzIK08mTkxxvejXvJBnNJIFizwD2RN0fIaONVboHI03gy2gqD8T610q8--_3vIcnPCCO0KsmP4ajbr11HwgvdXpCu2RZTODR6dnl1Xe6muN8Es8eJnHn_AIjARmA |
link.rule.ids | 230,314,727,780,784,864,885,2102,12056,21388,27924,27925,31719,31720,33744,33745,41120,42189,43310,43805,51576,53791,53793,73745,74302 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKwEXxJtAASNxAkXd2I7jnBBFrRborhBqpd4sP8all6Rssv8fT-JsWV7HJFY08Xg833gm3xDyJoJgqQppchDO50IWMq9LG3ITQ4lQy0rIgUxnuZKLM_H5vDxPB25dKquc9sRho_atwzPygxhsVzGWk6x-f_Ujx65RmF1NLTRukj1kTi9nZO_waPX12_Upi5AqYogpncnVQYceC0uIJP5QzfNyxyENvP1_A5t_1kz-ljgd_NHxPXI3AUn6YdT8fXIDmgfk1jKlyh8Sv5wa39KRGjek0znaBgpIa0wtFqT31KHi1_TSj4VD0FG_3lzQsUa8o30br-OeuH0NeDpl5B-Rs-Oj04-LPLVUyF3JZZ8XsgZvjI2xKK-YdDWwoEKEbJIbIyGACFXhaiuYBYadecD6uY9BjucmeGX5YzJr2gaeElpZVktvnVERIQjFrGU8RHhWzo2dA5cZeTvNq74amTP0kPHmSo9K0FhdhkrQZUYOcea3A5H0erjRri90siENCjjwytXGccHARqThyiKKLEMFwbmM7E9608kSO329bjLyevs42hAmRkwD7QbHFDFQj748yvFkVPNWEqakQM6yjFQ7C2BH1N0nzeX3gacbeY7i4s_Iu2mp_CLWv2bi2f8_4hW5vThdnuiTT6svz8kdhiAD29OU-2TWrzfwIkKk3r5MdvAT7g4QiQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVqq4IN6kFDASJ1C0G9txnBOi0FV57KpCVOrN8rP0kpTd7P_vOHG2LK9jEiua2DOebzyTbwBeIwgWshA699y6nItC5HVpQq4xlAi1qLjoyXQWS3Fyxj-fl-ep_mmdyirHPbHfqF1r4xn5FIPtCmM5QetpSGURpx_n765-5rGDVMy0pnYat2EPveKMTmDv6Hh5-u3mxIULiXhiTG0yOV1H7xXLiUT8uZrl5Y5z6jn8_wY8_6yf_C2J2vum-T24m0AleT9owX245ZsHsL9IafOH4BZjE1wy0OSGdFJH2kB8pDgmJhand8RGJViRSzcUEfk1cavNBRnqxdeka_Ea98fta7wjY3b-EZzNj79_OMlTe4Xclkx0eSFq77Q2GJeyigpbexpkQPgmmNbCB89DVdjacGo8jV16vHEzhwGPYzo4adhjmDRt458CqQythTNWS0QLXFJjKAsI1cqZNjPPRAZvxnlVVwOLhuqz30yqYRFUrDSLi6DKDI7izG8HRgLs_ka7ulDJnpSXnnlW2Vpbxqk3iDpsWaDIIlQ-WJvB4bhuKlnlWt3oUAavto_RnmKSRDe-3cQxBQbt6NdRjifDMm8loVLwyF-WQbWjADui7j5pLn_0nN2R8wgNIYO3o6r8Ita_ZuLg_x_xEvbRBNTXT8svz-AOjXgjdqopD2HSrTb-OaKlzrxIZnANlCAUtg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+stratification+of+early+breast+cancer+identifies+drug+targets+to+drive+stratified+medicine&rft.jtitle=NPJ+breast+cancer&rft.au=Bayani%2C+Jane&rft.au=Yao%2C+Cindy+Q.&rft.au=Quintayo%2C+Mary+Anne&rft.au=Yan%2C+Fu&rft.date=2017-02-15&rft.issn=2374-4677&rft.eissn=2374-4677&rft.volume=3&rft.issue=1&rft_id=info:doi/10.1038%2Fs41523-016-0003-5&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41523_016_0003_5 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2374-4677&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2374-4677&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2374-4677&client=summon |